1.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 and over Sponsor: NCI Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-06077, NCT00423852
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2005-0445, NCT00492817
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 20406, NCT00674427
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 25 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: CHNY-06-533, IRB AAAC3457, NCT00801931
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 and over Sponsor: Other Protocol IDs: 6895, 2323.00, NCT00867139
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 4T-03-1, NCT00183820
|
|
10.
|
Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UMN-2005NT018, UMN-0506M70866, UMN-MT2005-06, NOVARTIS-CZOL446EUS29, NCT00321932
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0609-11, IUCRO-0166, AVF4003s, NCT00393861
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: Under 21 at original diagnosis Sponsor: NCI Protocol IDs: COG-AGCT0521, AGCT0521, NCT00467051
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: UMN-2007LS072, UMN-2007LS072, UMN-MT2007-07, NCT00617929
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: NCI Protocol IDs: FHCRC-07156, 07156, CHNMC-07156, NCT00627601
|
|
16.
|
Phase: Phase I Type: Treatment Status: Active Age: 45 and under Sponsor: Other Protocol IDs: 2004-0079, NCT00502892
|
|
17.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: BCM-H-6676, H 6676, BCM-ETNA, NCT00608309
|
|
18.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00005124, NCT00586690
|
|
19.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 00005123, NCT00586703
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: VU-VICC-PHI-0814, VICCPHI0814, NLGC-NLG-2100, IRB#080257, VICTR-1855, NCT00788086
|
|
21.
|
Phase: No phase specified Type: Treatment Status: Active Age: Under 55 Sponsor: Other Protocol IDs: 561-2003, NCT00231309
|
|
22.
|
Phase: No phase specified Type: Treatment Status: Active Age: not specified Sponsor: Other Protocol IDs: 234, NCT00212407
|
|
23.
|
Phase: No phase specified Type: Supportive care, Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: WSU-D-2797, WSU-0504001728, NCT00293384
|
|
24.
|
Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06U.20, NCT00429143
|
|
25.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 months to 40 Sponsor: NCI Protocol IDs: CHNMC-03112, 03112, NCT00638898
|